drugset
Drugs / Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine
last change Jul 2013 re-read 3 minutes ago

Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine

Vaccine

Developed for
meningococcal infection
Investigated by
GlaxoSmithKline · Oxford University Hospitals NHS Trust · University of Oxford

Trials 1

today NCT01129518 · Ph 4
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01129518 Jun 2010 → Jul 2013 meningococcal infection University of Oxford Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01129518 ↗
Modality Vaccine “glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy” NCT01129518 ↗
Route Intramuscular “All vaccines will be administered intramuscularly.” NCT01129518 ↗